Drug Profile

Entinostat - EOC Pharma/Syndax Pharmaceuticals

Alternative Names: EDP-103; EOC 103; KHK-2375; MS-27-275; MS-275; SND 275; SNDX-275

Latest Information Update: 05 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Mitsui Pharmaceuticals; University of Tokyo
Developer EOC Pharma; Syndax Pharmaceuticals
Class Aniline compounds; Antineoplastics; Benzamides; Carbamates; Pyridines; Small molecules
Mechanism of Action Histone deacetylase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Registered HER2 negative breast cancer
Suspended Bladder cancer; Breast cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Follicular lymphoma; Hodgkin's disease; Leukaemia; Malignant melanoma; Myelodysplastic syndromes; Neuroendocrine tumours; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours; Triple negative breast cancer; Uveal melanoma

04 Mar 2026 Tianjin Medical University Cancer Institute and Hospital plans a phase II trial for HER2-negative-breast-cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in April 2026 (PO) (NCT07441486)
30 May 2025 Efficacy and adverse events data from a phase II trial in Bladder cancer presented at the 61^st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
31 Dec 2024 Syndax Pharmaceuticals has multiple provisional and non-provisional patent applications for entinostat in USA

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com